UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 10, 2023

IRADIMED CORPORATION
(Exact Name of Registrant as Specified in Its Charter)

001-36534
(Commission File Number)

Delaware
73-1408526
(State or Other Jurisdiction of Incorporation)
(I.R.S. Employer Identification No.)

1025 Willa Springs Dr., 
Winter Springs, FL 32708
(Address of principal executive offices, including zip code)

(407) 677-8022
(Registrant’s telephone number, including area code)

NOT APPLICABLE
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common stock, par value $0.0001
IRMD
NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Securities registered pursuant to Section 12(b) of the Act:

Title of each class:
  
Trading Symbol
  
Name of each exchange on which registered:
Common stock, par value $0.0001
  
IRMD
  
NASDAQ Capital Market






Item 8.01    Other Events.

On May 10, 2023, Iradimed Corporation issued a press release announcing that it was recently named on Forbes’ latest list of America’s Best Small Companies for 2023.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. and is incorporated herein by reference. The information contained herein, including the exhibit furnished herewith, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.
Description
104
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 10, 2023 IRADIMED CORPORATION  
       

By:
/s/ John Glenn  
  Name:
 John Glenn  
  Title:
 Chief Financial Officer  
       

: